8-K: Relay Therapeutics Reports Q1 2025 Financial Results and Corporate Updates; Cash Runway Extended into 2029

Relay Therapeutics announced its Q1 2025 financial results, highlighting a cash runway extended into 2029 and progress in its clinical programs.

Summary

• Relay Therapeutics reported its first quarter 2025 financial results on May 5, 2025.
• The company's cash runway has been extended into 2029 due to strategic cost reductions.
• Relay Therapeutics initiated the Phase 3 ReDiscover-2 trial and a Phase 1 trial for vascular malformations in Q1 2025.
• Cash, cash equivalents, and investments totaled approximately $710 million at the end of Q1 2025.
• Revenue for Q1 2025 was $7.7 million, compared to $10.0 million in Q1 2024.
• Research and development expenses were $73.8 million for Q1 2025, down from $82.4 million in Q1 2024.
• Net loss for Q1 2025 was $77.1 million, or $0.46 per share, compared to a net loss of $81.4 million, or $0.62 per share, in Q1 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the extended cash runway and progress in clinical trials, despite the reported net loss and revenue decrease. The strategic cost reductions are viewed favorably.

Positives

• The company's cash runway has been extended into 2029, providing financial stability for ongoing clinical programs.
• Initiation of the Phase 3 ReDiscover-2 trial for breast cancer and the Phase 1 trial for vascular malformations demonstrates progress in clinical development.
• Strategic cost reductions are expected to fully fund key value drivers, including the ReDiscover-2 trial and vascular malformations program.
• Relay Therapeutics has a strong cash position with approximately $710 million in cash, cash equivalents, and investments.
• An abstract was accepted to ASCO for an update of the Phase 1b ReDiscover trial of RLY-2608 + fulvestrant.

Negatives

• Revenue decreased to $7.7 million in Q1 2025 from $10.0 million in Q1 2024.
• The company reported a net loss of $77.1 million for Q1 2025.
• A reduction in force of approximately 70 people was implemented as part of strategic cost reductions.

Risks

• Restructuring activities may be more costly or time-consuming than expected and may not achieve their intended results.
• The internal and external costs required for ongoing and planned activities may be higher than expected, potentially impacting the company's cash usage.
• Global economic uncertainty, geopolitical instability, and public health epidemics could impact the timing and anticipated results of clinical trials.
• Preliminary or interim results of preclinical or clinical trials may not be predictive of future or final results.
• The company's ability to successfully demonstrate the safety and efficacy of its drug candidates is subject to risk.

Future Outlook

Relay Therapeutics expects its current cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2029. The company is focused on executing its clinical programs and advancing its pipeline.

Management Comments

• 2025 is a year of execution across a range of high value clinical programs, said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
• The ongoing changes to our cost base are designed to enable a full funding of key initiatives including generating topline data from the ReDiscover-2 trial and clinical proof-of-concept data in vascular malformations.

Industry Context

Relay Therapeutics is operating in the competitive precision medicine space, focusing on targeted oncology and genetic disease indications. The company's approach of combining computational and experimental technologies aims to differentiate it from other biotech companies.

Comparison to Industry Standards

• Relay Therapeutics' approach to drug discovery, combining computational and experimental technologies, is similar to that of companies like Schrodinger and Recursion Pharmaceuticals, which also leverage technology to improve drug development.
• The company's focus on targeted oncology aligns with the strategies of companies like Amgen and Novartis, which are investing heavily in precision medicine.
• Relay Therapeutics' cash runway into 2029 provides a longer period of financial stability compared to some smaller biotech companies that may need to raise capital more frequently.

Stakeholder Impact

• Shareholders may be positively impacted by the extended cash runway and progress in clinical trials.
• Employees may be affected by the reduction in force, but the company's focus on key initiatives could provide future opportunities.
• Patients may benefit from the development of new therapies for cancer and genetic diseases.
• Suppliers and creditors may be impacted by the company's cost reduction measures.

Next Steps

• Initiation of Phase 3 ReDiscover-2 trial in mid-2025.
• Continued advancement of ongoing triplet cohorts with RLY-2608 + fulvestrant + atirmociclib or ribociclib.
• Planning for development of next-generation endocrine therapy combinations with RLY-2608.
• Advancement of Fabry and NRAS programs to Investigational New Drug application (IND) readiness.
• Advancement of one research-stage program.

Key Dates

Keywords

Relay Therapeutics, financial results, clinical trials, RLY-2608, cash runway, precision medicine, oncology, vascular malformations, breast cancer, cost reductions